Bradley Dixon, MD
Associate Professor, Pediatrics-Nephrology
Medical School:
- MD, University of Tennessee Health Science Center College of Medicine (1999)
- BA, The College of Wooster (OH) (1995)
- Cincinnati Children's Hospital Medical Center Program, Chief Resident, Pediatrics (2003)
- Cincinnati Children's Hospital Medical Center Program, Pediatric Nephrology (2006)
Research Interests
My research interests are primarily focused on diseases of the kidney caused by abnormalities in the complement system, specifically atypical hemolytic uremic syndrome (aHUS), C3 Glomerulopathy (C3G), and Membranoproliferative Glomerulonephritis (MPGN). These interests are focused on development and improvement of blood tests that are used to diagnose these diseases, as well as clinical trials in new medications being developed to treat these diseases. I also have a clinical research interest in the wide variety of kidney diseases that have a genetic cause, especially cystic kidney diseases but also tubular diseases like Bartter syndrome and Gitelman syndrome, and glomerular diseases like Alport syndrome.
Publications
- Wenderfer SE, Chang JC, Goodwin Davies A, Luna IY, Scobell R, Sears C, Magella B, Mitsnefes M, Stotter BR, Dharnidharka VR, Nowicki KD, Dixon BP, Kelton M, Flynn JT, Gluck C, Kallash M, Smoyer WE, Knight A, Sule S, Razzaghi H, Bailey LC, Furth SL, Forrest CB, Denburg MR, Atkinson MA. Using a Multi-Institutional Pediatric Learning Health System to Identify Systemic Lupus Erythematosus and Lupus Nephritis: Development and Validation of Computable Phenotypes. Clin J Am Soc Nephrol. 2022 Jan;17(1):65-74. PubMed PMID: 34732529
- Nester C, Appel GB, Bomback AS, Bouman KP, Cook HT, Daina E, Dixon BP, Rice K, Najafian N, Hui J, Podos SD, Langman CB, Lightstone L, Parikh SV, Pickering MC, Sperati CJ, Trachtman H, Tumlin J, de Vries AP, Wetzels JFM, Remuzzi G. Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies. Am J Nephrol. 2022 Nov 24;:1-14. [Epub ahead of print] PubMed PMID: 36423588
- Podos SD, Trachtman H, Appel GB, Bomback AS, Dixon BP, Wetzels JFM, Cook HT, Parikh SV, Pickering MC, Tumlin J, Langman CB, Lightstone L, Sperati CJ, Daina E, Bouman KP, Rice K, Thanassi JA, Huang M, Nester C, Remuzzi G. Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan. Am J Nephrol. 2022 Nov 18;:1-12. [Epub ahead of print] PubMed PMID: 36404708
- Stotter BR, Cody E, Gu H, Daga A, Greenbaum LA, Duong MD, Mazo A, Goilav B, Boneparth A, Kallash M, Zeid A, Seeherunvong W, Scobell RR, Alhamoud I, Carter CE, Shah S, Straatmann CE, Dixon BP, Cooper JC, Nelson RD, Levy DM, Brunner HI, Verghese PS, Wenderfer SE. Acute kidney injury requiring kidney replacement therapy in childhood lupus nephritis: a cohort study of the Pediatric Nephrology Research Consortium and Childhood Arthritis and Rheumatology Research Alliance. Pediatr Nephrol. 2022 Oct 17. [Epub ahead of print] PubMed PMID: 36251074
- Goodwin Davies AJ, Xiao R, Razzaghi H, Bailey LC, Utidjian L, Gluck C, Eckrich D, Dixon BP, Deakyne Davies SJ, Flynn JT, Ranade D, Smoyer WE, Kitzmiller M, Dharnidharka VR, Magnusen B, Mitsnefes M, Somers M, Claes DJ, Burrows EK, Luna IY, Furth SL, Forrest CB, Denburg MR. Skeletal Outcomes in Children and Young Adults with Glomerular Disease. J Am Soc Nephrol. 2022 Dec;33(12):2233-2246. PubMed PMID: 36171052
- Abu Jawdeh BG, Campos-Naciff B, Meganathan K, Steve Woodle E, Dixon BP. The Role of Complement Split-products as Biomarkers for Acute Antibody-mediated Rejection of Kidney Allografts. Transplant Direct. 2022 Sep;8(9):e1366. PubMed PMID: 35935026
- Chan M, Hanna MG, Willard N, Treece A, Dixon BP. Hypocomplementemic Atypical IgA Vasculitis: A Case Report. Front Pediatr. 2022;10:886371. PubMed PMID: 35757129
- Dixon BP, Sabus A. Ravulizumab 100 mg/mL formulation reduces infusion time and frequency, improving the patient and caregiver experience in the treatment of atypical haemolytic uraemic syndrome. J Clin Pharm Ther. 2022 Jul;47(7):1081-1087. PubMed PMID: 35304755
- Benoit SW, Fukuda T, VandenHeuvel K, Witte D, Fuller C, Willis J, Dixon BP, Drake KA. Case Report: Atypical HUS Presenting With Acute Rhabdomyolysis Highlights the Need for Individualized Eculizumab Dosing. Front Pediatr. 2022;10:841051. PubMed PMID: 35281224
- Wenderfer SE, Chang JC, Goodwin Davies A, Luna IY, Scobell R, Sears C, Magella B, Mitsnefes M, Stotter BR, Dharnidharka VR, Nowicki KD, Dixon BP, Kelton M, Flynn JT, Gluck C, Kallash M, Smoyer WE, Knight A, Sule S, Razzaghi H, Bailey LC, Furth SL, Forrest CB, Denburg MR, Atkinson MA. Using a Multi-Institutional Pediatric Learning Health System to Identify Systemic Lupus Erythematosus and Lupus Nephritis: Development and Validation of Computable Phenotypes. Clin J Am Soc Nephrol. 2022 Jan;17(1):65-74. PubMed PMID: 34732529
- Ariceta G, Dixon BP, Kim SH, Kapur G, Mauch T, Ortiz S, Vallee M, Denker AE, Kang HG, Greenbaum LA. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. Kidney Int. 2021 Jul;100(1):225-237. PubMed PMID: 33307104
- Nitzan-Luques A, Slae M, Zugayar D, Dixon BP, Meir K, Volovelsky O. Neonatal thrombotic microangiopathy secondary to factor I variant with Hirschsprung disease. J Nephrol. 2021 Feb;34(1):241-245. PubMed PMID: 32514992
- Stenson EK, You Z, Reeder R, Norris J, Scott HF, Dixon BP, Thurman JM, Frazer-Abel A, Mourani P, Kendrick J. Complement activation fragments are increased in critically ill pediatric patients with severe acute kidney injury. Kidney360 Oct 2021, doi:10.34067/KID.0004542021.
- Ariceta G, Dixon BP, Kim SH, Kapur G, Mauch T, Ortiz S, Vallee M, Denker AE, Kang HG, Greenbaum LA. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. Kidney Int. 2020 Dec 8. [Epub ahead of print] PubMed PMID: 33307104
- Marchbank KJ, Frazer-Abel A, Dragon-Durey MA, Dixon BP. Editorial: Autoantibodies in Kidney Diseases. Front Immunol. 2020;11:591338. PubMed PMID: 33042166
- Nitzan-Luques A, Slae M, Zugayar D, Dixon BP, Meir K, Volovelsky O. Neonatal thrombotic microangiopathy secondary to factor I variant with Hirschsprung disease. J Nephrol. 2020 Jun 8. [Epub ahead of print] PubMed PMID: 32514992
- Denburg MR, Razzaghi H, Bailey LC, Soranno DE, Pollack AH, Dharnidharka VR, Mitsnefes MM, Smoyer WE, Somers MJG, Zaritsky JJ, Flynn JT, Claes DJ, Dixon BP, Benton M, Mariani LH, Forrest CB, Furth SL. Using Electronic Health Record Data to Rapidly Identify Children with Glomerular Disease for Clinical Research. J Am Soc Nephrol. 2019 Dec;30(12):2427-2435. PubMed PMID: 31732612
- Shin HS, Nester CM, Dixon BP. Comorbidity of inflammatory bowel disease with atypical hemolytic uremic syndrome in pediatric patients. Clin Nephrol Case Stud. 2019;7:35-40. PubMed PMID: 31312592
- Kleene SJ, Siroky BJ, Landero-Figueroa JA, Dixon BP, Pachciarz NW, Lu L, Kleene NK. The TRPP2-dependent channel of renal primary cilia also requires TRPM3. PLoS One. 2019;14(3):e0214053. PubMed PMID: 30883612
- Benoit SW, Dixon BP, Goldstein SL, Bennett MR, Lane A, Lounder DT, Rotz SJ, Gloude NJ, Lake KE, Litts B, Davies SM. A novel strategy for identifying early acute kidney injury in pediatric hematopoietic stem cell transplantation. Bone Marrow Transplant. 2019 Sep;54(9):1453-1461. PubMed PMID: 30700793
- Cody EM, Dixon BP. Hemolytic Uremic Syndrome. Pediatr Clin North Am. 2019 Feb;66(1):235-246. PubMed PMID: 30454746
Practice Locations
Children's Hospital Colorado Anschutz Medical Campus
13123 East 16th Ave
Aurora, CO 80045
720-777-1234
Hospital Affiliation
13123 East 16th Ave
Aurora, CO 80045
720-777-1234
Hospital Affiliation
- Children's Hospital Colorado
Specialty Information
Specialties
- Pediatric Nephrology, Board Certification (2008)
- Pediatrics, Board Certification (2002, 2012)
- Kidneys and Urinary System - Proteinuria
- Kidneys and Urinary System
- Kidneys and Urinary System - Polycystic Kidney Disease
- Kidneys and Urinary System - Nephropathy (Nephrosis)
- Kidneys and Urinary System - Kidney Disease
Clinical Interests
One of my primary clinical interests focuses on the ways in which the complement system, a series of proteins within the immune system, can cause kidney diseases in children and adults. I also have a strong clinical interest in the large number of kidney conditions that have a genetic cause.
Care Philosophy
I treat patients the way I would want my own family to be treated by a health care provider. I strive to take as much time as needed to listen to the patient's and family's concerns, and explain the condition as well as testing and treatment options.
One of my primary clinical interests focuses on the ways in which the complement system, a series of proteins within the immune system, can cause kidney diseases in children and adults. I also have a strong clinical interest in the large number of kidney conditions that have a genetic cause.
Care Philosophy
I treat patients the way I would want my own family to be treated by a health care provider. I strive to take as much time as needed to listen to the patient's and family's concerns, and explain the condition as well as testing and treatment options.
General Information
Medical Schools:
- MD, University of Tennessee Health Science Center College of Medicine (1999)
Undergraduate Schools:
- BA, The College of Wooster (OH) (1995)
Residency Programs:
- Cincinnati Children's Hospital Medical Center Program, Chief Resident, Pediatrics (2003)
Fellowships:
- Cincinnati Children's Hospital Medical Center Program, Pediatric Nephrology (2006)